ArticleOncotarget2016
Combination of metronomic cyclophosphamide and dietary intervention inhibits neuroblastoma growth in a CD1-nu mouse model.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Cancer Treatment With the Ketogenic Diet: A Systematic Review and Meta-analysis of Animal Studies.Frontiers in nutrition · 2021Pooled it
- Ketogenic diets in medical oncology: a systematic review with focus on clinical outcomes.Medical oncology (Northwood, London, England) · 2020Pooled it
- The nutrigenomic-epigenetic axis in cancer: from dietary bioactives to precision oncology.Nutrition & metabolism · 2026Review
- Reprogramming lipid metabolism in pediatric cancers.Oncogenesis · 2026Review
- Article
- Hyperlipidemia drives tumor growth in a mouse model of obesity-accelerated breast cancer growth.Cancer & metabolism · 2025Article
- Ketogenic diet with oxyresveratrol and zinc inhibits glioblastoma and restores memory function and motor coordination.Oncology research · 2025Article
- Overcoming immunosuppression in cancer: how ketogenic diets boost immune checkpoint blockade.Cancer immunology, immunotherapy : CII · 2024Review
- Effects of dietary intervention on human diseases: molecular mechanisms and therapeutic potential.Signal transduction and targeted therapy · 2024Review
- A ketogenic diet rich in fish oil is superior to other fats in preventing NNK-induced lung cancer in A/J mice.Scientific reports · 2024Article
- Metabolic protein kinase signalling in neuroblastoma.Molecular metabolism · 2023Review
- Triple Therapy with Metformin, Ketogenic Diet, and Metronomic Cyclophosphamide Reduced Tumor Growth in MYCN-Amplified Neuroblastoma Xenografts.Metabolites · 2023Article
- Article
- Metronomic Chemotherapy in Pediatric Oncology: From Preclinical Evidence to Clinical Studies.Journal of clinical medicine · 2022Review
- Ketogenic diets slow melanoma growth in vivo regardless of tumor genetics and metabolic plasticity.Cancer & metabolism · 2022Article
- Ketogenic diet for human diseases: the underlying mechanisms and potential for clinical implementations.Signal transduction and targeted therapy · 2022Review
- Article
- Molecular Iodine/Cyclophosphamide Synergism on Chemoresistant Neuroblastoma Models.International journal of molecular sciences · 2021Article
- Pan-Cancer Analysis of Glycolytic and Ketone Bodies Metabolic Genes: Implications for Response to Ketogenic Dietary Therapy.Frontiers in oncology · 2021Article
- The Role of Diet in Cancer Prevention and Chemotherapy Efficacy.Annual review of nutrition · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMYCN-amplification in high-grade Neuroblastoma (NB) tumors correlates with increased vascularization and therapy resistance. This study combines an anti-angiogenic approach with targeting NB metabolism for treatment. METHODS AND
resultsMetronomic cyclophosphamide (MCP) monotherapy significantly inhibited NB growth and prolonged host survival. Growth inhibition was more pronounced in MYCN-amplified xenografts. Immunohistochemical evaluation of this subtype showed significant decrease in blood vessel density and intratumoral hemorrhage accompanied by blood vessel maturation and perivascular fibrosis. Up-regulation of VEGFA was not sufficient to compensate for the effects of the MCP regimen. Reduced Bcl-2 expression and increased caspase-3 cleavage were evident. In contrast non MYCN-amplified tumors developed resistance, which was accompanied by Bcl-2-up-regulation. Combining MCP with a ketogenic diet and/or calorie-restriction significantly enhanced the anti-tumor effect. Calorie-restricted ketogenic diet in combination with MCP resulted in tumor regression in all cases.
conclusionsOur data show efficacy of combining an anti-angiogenic cyclophosphamide dosing regimen with dietary intervention in a preclinical NB model. These findings might open a new front in NB treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.